Oncotarget

Reviews:

Preclinical evidence of ghrelin as a therapeutic target in epilepsy

Tongtong Ge, Wei Yang, Jie Fan and Bingjin Li _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:59929-59939. https://doi.org/10.18632/oncotarget.18349

Metrics: PDF 1198 views  |   HTML 2398 views  |   ?  


Abstract

Tongtong Ge1,*, Wei Yang1,*, Jie Fan1 and Bingjin Li1

1Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun 130041, PR China

*These authors contributed equally to this work

Correspondence to:

Bingjin Li, email: libingjin@jlu.edu.cn

Keywords: ghrelin, epilepsy, hippocampus, memory, neuroprotection

Received: March 08, 2017     Accepted: May 22, 2017     Published: June 02, 2017

ABSTRACT

Ghrelin, an orexigenic peptide synthesized by endocrine cells of the gastric mucosa, plays a major role in inhibiting seizures. However, the underlying mechanism of ghrelin’s anticonvulsant action is still unclear. Nowadays, there are considerable evidences showing that ghrelin is implicated in various neurophysiological processes, including learning and memory, neuroprotection, neurogenesis, and inflammatory effects. In this review, we will summarize the effects of ghrelin on epilepsy. It may provide a comprehensive picture of the role of ghrelin in epilepsy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18349